MGNX - MacroGenics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

MacroGenics, Inc.

9704 Medical Center Drive
Rockville, MD 20850
United States
301 251 5172
http://www.macrogenics.com

SectorHealthcare
IndustryBiotechnology
Full-time employees384

Key executives

NameTitlePayExercisedYear born
Dr. Scott KoenigCEO, Pres & Director905.44k466k1952
Mr. James KarrelsSr. VP, CFO & Sec.533.25k145.22k1967
Dr. Ezio BonviniSr. VP of Research, Chief Scientific Officer & Acting Head of Clinical Devel.575.14kN/A1954
Mr. Eric Blasius RisserSr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer531.38k198.9k1973
Anna Krassowska Ph.D.VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. It has strategic collaborations with Incyte Corporation; Zai Lab Limited; and I-Mab Biopharma. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Corporate governance

MacroGenics, Inc.’s ISS governance QualityScore as of 7 December 2019 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.